May 1, 2024, 04:54
Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine
Howard McLeod, Central Director, Founder and Advisor at Precision Medicine, shared on LinkedIn:
“The USA cancer community might be late to adopt Dihydropyrimidine dehydrogenase (DPYD) testing to avoid severe/fatal toxicity from commonly used chemotherapy, but the tide has finally changed. The recent Food and Drug Administration (FDA) package insert change is followed by very successful implementation at Dana-Farber Cancer Institute. With data from community centers, such as Atrium Health and St. Elizabeth Healthcare, there are no more excuses for rest of the field.”
Additional information
Source: Howard McLeod/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 16:25
Oct 23, 2024, 16:03
Oct 23, 2024, 15:44
Oct 23, 2024, 15:44
Oct 23, 2024, 15:42
Oct 23, 2024, 15:15
Oct 23, 2024, 15:07